カテゴリ： Kuick Research, 医療/バイオ

PARP阻害剤がん治療の世界市場

◆英語タイトル：Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2023
◆商品コード：DATA809009
◆発行会社（リサーチ会社）：KuicK Research
◆発行日：2018年4月
◆ページ数：200
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆調査対象地域：グローバル
◆販売価格オプション（消費税別）
Single UserUSD2,200 ⇒換算￥242,000見積依頼/購入/質問フォーム
Multi UserUSD4,000 ⇒換算￥440,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuicK Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
※KuicK Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

 【レポートの概要】

“Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2023” report highlights:
• Current Market Trends & Development Scenario
• Drug Availability, Dosage & Treatment Schedule
• Commercially Available Drugs Price Analysis
• Global Cancer PARP Inhibitors Clinical Pipeline Overview: 31 Drugs
• Clinical & Patent Insight on Commercially Available Drugs: 3 Drugs
• Market Segmentation by Drug Patent & Dales

Conventional therapies like surgery, radiotherapy and chemotherapies are currently the dominant form of cancer treatment globally. However, majority of these methods have several limitations with multiple adverse effects which has led to the emergence of much more innovative approach, collectively known as targeted therapies. Targeted cancer therapy segment currently flourishes with several types of therapeutics among which PARP inhibitors have gained immense popularity due to their superior efficacy to conventional therapeutics.

Inhibitors include drugs or substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer. PARP inhibitors are recent entrants in the targeted therapy segment which have gained worldwide popularity as the most common type treatment in certain clinical indications like ovarian cancer and breast cancer.

Poly-ADP Ribose Polymerase or PARP are special proteins that play a key role in assisting damaged cells to repair themselves. The initial clinical testing of PARP inhibitors began nearly a decade ago, following the discovery that these agents in vitro had heightened anticancer activity in cancer cells that harbored BRCA mutations compared to BRCA wild-type cancer cells with intact DNA repair.

Research proved that fault in either of BRCA 1 and BRCA 2 genes have an increased risk of certain types of cancer such as breast cancer, ovarian cancer and prostate cancer. Cells are less likely to repair themselves if there is a fault in one or both of these genes. Blocking PARP with a PARP inhibitor showed impressive results in preventing the proliferation of cancer cells by interfering with their DNA repair mechanism and killing them, thus resulting in a therapeutic outcome.

Currently, there are 3 PARP inhibitors that have been approved for use in patients with suspected or confirmed BRCA-mutated advanced ovarian cancer that has been treated with 3 or more prior lines of chemotherapy. Olaparib (Lynpraza) was the first PARP inhibitor to receive approval in 2014 followed by Rucaparib in 2016 and Niraparib in 2017.

Trends show that the cancer therapy market is steadily shifting from conventional therapeutics to modern therapeutics due to their better safety, efficacy and specificity; thus creating an excellent opportunity for promising therapeutics like PARP inhibitors.

PARP inhibitors have proved to be a commercial success in the modern cancer therapeutic segment. For instance, Lynpraza(Olaparib), marketed by AstraZeneca reported global sales of over US$ 400 Million in 2017; making it one of the most profitable cancer therapy drugs of the year. Lynpraza sales have more than doubled since its approval which projects an optimistic growth in the future. Olaparib is followed by Niraparib with sales of over US$ 109 Million during first nine months of commercial launch. Rucaparib – the most recent PARP inhibitor to enter the market is estimated to generate revenue of over US$ 40 Million by the end of 2018.

The US currently dominates the global PARP inhibitors market leading both in marketing and research followed by Europe. Involvement of regions like South Korea, Japan and Middle East has led to better market penetration and overall better market growth.

The demand for PARP inhibitors has grown exponentially with the increasing incidence of cancer. Further, their enhanced efficacy in cancer treatment when combined with conventional therapeutics like chemotherapy and radiation therapy has led to an exponential growth in sales; which is further strengthened by a robust clinical pipeline under development. With several favorable factors paving the path for success, PARP inhibitors could be one of the leading cancer therapeutics of the future

KuicK Research Analysis of the global PARP inhibitors market provides an in-depth analysis of the current market scenario, trends, dynamics and recent advances that might have an impact on the PARP inhibitors market. Key data like pricing of drugs, sales and cost of therapy per patient have been used to draw an accurate analysis of the PARP inhibitors market. Finally, KuicK Research analysis of forecast and projections regarding the future of PARP Inhibitors market indicate an exciting opportunity waiting in this highly profitable segment of cancer therapy.

【レポートの目次】

1. Introduction to Poly (ADP-Ribose) Polymerase Inhibitors
1.1 PARP Inhibitors as Unique Cancer Therapy
1.2 Evolutionary Aspects of PARP Inhibitors
1.3 Prelude to PARP Proteins & their Inhibitors

2. PARP Proteins: An Attractive Target for Developing Cancer Therapeutics
2.1 Structural Organization of Target Site of PARP Inhibitors
2.2 Structural Organization of PARP Inhibitors

3. Therapeutic Exploitation of Role of PARP Proteins in Normal Cells & Cancer Cells
3.1 Significance of PARP Proteins in Normal Cells
3.2 Significance of PARP Proteins in Tumorigenesis: Affecting Cell Division & DNA Repair
3.3 PARP Inhibitors: Distinct Modes of Action for Eliminating Cancer Cells

4. Global Poly (ADP-Ribose) Polymerase Inhibitors Clinical Pipeline Overview

5. Commercially Available Poly (ADP-Ribose) Polymerase Inhibitors (PARP Inhibitors) as Cancer Monotherapy
5.1 Olaparib
5.1.1 Availability, Dosage & Treatment Schedule
5.1.2 Price Analaysis
5.2 Rucaparib
5.2.1 Availability, Dosage & Treatment Schedule
5.2.2 Price Analysis
5.3 Niraparib
5.3.1 Availability, Dosage & Treatment Schedule
5.3.2 Price Analysis
5.4 Promising PARP Inhibitors in Clinical Pipeline: Efficiency, Dosage & Expected Price
5.4.1 Talazoparib
5.4.2 Veliparib

6. Global PARP Inhibitor Cancer Therapy Current Market Scenario
6.1 PARP Inhibitor Market Outline
6.2 Market Segmentation by Patent
6.3 Market Segmentation by Drug Sales
6.4 Market Trends

7. PARP Inhibitors with Conventional Cancer Therapy: Efficacy, Dosage & Price Analysis
7.1 PARP Inhibitors with Chemotherapy
7.1.1 Temozolomide
7.1.2 Platinum Salts
7.1.3 Taxanes
7.1.4 Gemcitabine
7.1.5 Topoisomerase Inhibitors/Poisons
7.2 PARP Inhibitors in Combination with Radiotherapy

8. Improved Efficacy of PARP Inhibitors by Modern Cancer Therapies
8.1 Combination of PARP Inhibitors & Targeted Therapies
8.1.1 PARP Inhibitors with EGFR Inhibitors
8.1.2 PARP Inhibitors with VEGFR Inhibitors
8.1.3 PARP Inhibitors with PI3K/mTOR Inhibitors
8.1.4 PARP Inhibitors with Trastuzumab
8.1.5 Anti-endocrine agents
8.1.6 HSP90 Inhibitors
8.1.7 IGF-1R & HDAC Inhibitors
8.2 PARP Inhibitors in Combination with Immunotherapies

9. Factors Driving Global PARP Inhibitors Market
9.1 Consecutive Approvals of Several PARP Inhibitors & Anticipated Approvals in the Nearby Future
9.2 Strong clinical Pipeline
9.3 Large Patient Base
9.4 Commercial Success of Approved PARP Inhibitors

10. Global PARP Inhibitor Market Challenges
10.1 Scientific Limitations and the Number of Side Effects
10.2 Tedious approval process

11. Global PARP Inhibitors Market Future Forecast
11.1 PARP Inhibitors in the Pipeline: Shaping the Future of Ineffectively Treated Cancer
11.1.1 PARP Inhibitors for Prostate Cancer
11.1.2 PARP Inhibitors for Lung Cancer
11.1.3 PARP Inhibitors in Pancreatic Cancer
11.2 Market Opportunity

12. Global Cancer PARP Inhibitors Clinical Pipeline by Company, Indication & Phase
12.1 Preclinical
12.2 Clinical
12.3 Phase-I
12.4 Phase-I/II
12.5 Phase-II
12.6 Phase-III

13. Marketed Cancer PARP Inhibitors Clinical Insight by Company & Indication
13.1 Olaparib (Lynparza)
13.2 Niraparib (Zejula)
13.3 Rucaparib (Rubraca)

14. Competitive Landscape
14.1 2X Oncology
14.2 Abott Laboratories
14.3 Cephalon
14.4 Checkpoint Therapeutics
14.5 Eisai Co. Ltd
14.6 IMPACT Therapeutics
14.7 Jeil Pharmaceuticals
14.8 KuDOS Pharmaceuticals
14.9 Kyowa Hakko Kirin
14.10 Lead Therapeutics
14.11 Shanghai De Novo Pharmatech

Figure 1-1: History & Evolution of PARP Inhibitors
Figure 1-2: Biochemistry & Biological Functions Of Poly ADP-Ribosylation Reaction Mediated by Poly (ADP-Ribose) Polymerase (PARP) Enzymes
Figure 2-1: Structural Organization of PARP-1 & PARP-2 Enzymes
Figure 3-1: PARP Proteins in DNA Damage Repair Mechanism
Figure 3-2: Importance of PARP in DNA Repair Mechanism in Normal Cells
Figure 3-3: Dual Action of PARP inhibition for Cancer Treatment
Figure 4-1: Global – Cancer PARP Inhibitors Pipeline by Phase (%), 2018 till 2023
Figure 4-2: Global – Cancer PARP Inhibitors Pipeline by Phase (Number), 2018 till 2023
Figure 4-3: Global – Cancer PARP Inhibitors Pipeline by Phase (%),2018 till 2023
Figure 4-4: Global – Cancer PARP Inhibitors Pipeline by Phase (Number), 2018 till 2023
Figure 5-1: Progression Free Survival in Patients with Platinum-Sensitive, Relapsed, BRCA-mutant Ovarian Cancer by Using a PARP Inhibitor for 30 Months
Figure 5-2: Olaparib - Available Concentrations (mg), 2018
Figure 5-3: Olaparib - Dosage Analysis (mg/Day)
Figure 5-4: Olaparib - 150mg & 100mg Tablet Dosage Analysis (mg/12 hour) By Tablet Concentration
Figure 5-5: Olaparib - 50mg Tablet Dosage Analysis (Number of Capsules/Day)
Figure 5-6: Olaparib - Price Analysis by Type (US$/Unit), 2018
Figure 5-7: Olaparib - Price Analysis by Type (US$/Packet), 2018
Figure 5-8: Olaparib - Average Price Analysis for Breast & Ovarian Cancer Treatment (US$), 2018
Figure 5-9: Olaparib - Ovarian Cancer Maintenance Therapy Cost Analysis for Reoccurent BRCA Mutated Population (US$), 2018
Figure 5-10: Olaparib - Total Cost Analysis for Ovarian Cancer Maintenance Therapy for Reoccurent BRCA Mutated Population (US$), 2018
Figure 5-11: Olaparib - Ovarian Cancer Maintenance Therapy Cost Analysis for Platinum Sensitive Germline BRCA Mutated Cancer Population (US$), 2018
Figure 5-12: Rucaparib - Available Concentrations of Drug (mg)
Figure 5-13: Rucaparib - Dosage Analysis (mg/Day), 2018
Figure 5-14: Rucaparib - 300mg & 200mg Tablet Dosage Analysis (mg/12 hour) By Tablet Concentration
Figure 5-15: Rucaparib - Price Analysis (US$), 2018
Figure 5-16: Rucaparib - Average Price Analysis for Reoccurent BRCA Mutated Cancer Treatment (US$), 2018
Figure 5-17: Rucaparib - Ovarian Cancer Maintenance Therapy Cost Analysis for Reoccurent BRCA Mutated Population (US$), 2018
Figure 5-18: Rucaparib - Total Cost Analysis for Maintenance Therapy for Reoccurent BRCA Mutated Cancer Population (US$), 2018
Figure 5-19: Niraparib - Dosage Analysis (mg/Day)
Figure 5-20: Niraparib - Price Analysis (US$), 2018
Figure 5-21: Niraparib - Average Price Analysis for Breast & Ovarian Cancer Treatment (US$), 2018
Figure 5-22: Niraparib - Maintenance Therapy Cost Analysis for Germline BRCA Mutated Cancer Population (US$), 2018
Figure 5-23: Niraparib - Maintenance Therapy Cost Analysis for Non - Germline BRCA Mutated Cancer Population (US$), 2018
Figure 5-24: Niraparib - Complete Cancer Treatment Cost Analysis
Figure 5-25: Talazoparib – Upcoming Concentration (mg), 2018
Figure 5-26: Talazoparib - Expected Price Analysis by Concentration (US$), 2018
Figure 5-27: Veliparib - Treatment Course Analysis indicated in Clinical Trials
Figure 5-28: Veliparib - Dosage Analysis indicated in Clinical Trials (mg)
Figure 5-29: Overall Survival in Patients with Breast Cancer Treated with Carboplatin + Paclitaxel with Veliparib v/s without Veliparib (Months)
Figure 6-1: Global – Lynparza (Olaparib) Patent Approval & Expiration Year by Drug Form, 2018
Figure 6-2: Lynparza (Olaparib) - Number of Granted Patents & Applications, 2018
Figure 6-3: US - Lynparza (Olaparib) Patent Analysis by Number, 2018
Figure 6-4: Global – Lynparza (Olaparib) Patent Analysis by Approved Drug Formulations, 2018
Figure 6-5: Global – Rubraca (Rucaparib) Patent Aprroval & Expiration Year, 2018
Figure 6-6: Rucaparib (Rubraca) - Number of Granted Patents & Applications, 2018
Figure 6-7: Global – Zejula (Niraparib) Patent Approval & Expiration Year, 2018
Figure 6-8: Zejula (Niraparib) - Granted Patents & Applications, 2018
Figure 6-9: Global – Lynparza (Olaparib) Sales (US$ Million), 2015-2017
Figure 6-10: Global – Rubraca (Rucaparib) Sales (US$ Milion), 2017
Figure 6-11: Global – Zejula (Niraparib) Sales (US$ Million), Q1’2017 & Q2’2017
Figure 6-12: Global – PARP Inhibitors End Users (Number of Patients/Year), 2018
Figure 7-1: Tolerable Dosage of Rucaparib & Temozolomide Combination Therapy in Clinical Trials for Advanced Malignancy (mg/m2)
Figure 7-2: Study of Veliparib + Temozolomide Showing Improved Survival of Patients with Metastatic Melanoma (Months)
Figure 7-3: Estimated Glioblastoma Treatment Cost for Temozolomide + PARP Inhibitor Therapy, (US$/Cycle)
Figure 7-4: Olaprib & Paclitaxel Combination Therapy Dosage Analysis for Metastatic Gastric Cancer (mg/Day & mg/m2/Day)
Figure 7-5: Olaprib & Paclitaxel Combination Therapy Dosage Analysis for Metastatic Gastric Cancer (Administeration/Cycle)
Figure 7-6: Olaparib & Paclitaxel Combination Therapy Cost Analysis for Metastatic Gastric Cancer (US$/Cycle)
Figure 7-7: Overall Survival of Patients with Metastatic Gastic Cancer with Paclitaxel Chemotherapy vs Combination Therapy with Olaparib (Months)
Figure 7-8: Overall Survival in Patients with Triple-Negative Breast Cancer Treated with Gemiciabine & Carboplatin Chemotherapy vs Combination Therapy with Iniparib (Months)
Figure 8-1: Overall Progression Free Survival in Patients with Recurrent Platinum-Sensitive High-Grade Serous or Endometrioid Ovarian Cancer Treated with Cediranib + Olaparib v/s Olaparib Monotherapy (Months), 2018
Figure 8-2: Olaparib & Cediranib Combination Therapy Dosage Analysis as per Clinical Trials (mg/Day)
Figure 9-1: Expected Approval of PARP Inhibitors in the Nearby Future
Figure 11-1: US - PARP Inhibitor Market Opprtunity in Ovarian Cancer by Patient Base Undergoing Treatment
Figure 11-2: US - PARP Inhibitor Market Opprtunity in Breast Cancer by Patient Base Undergoing Treatment


Table 11-1: Ongoing Clinical Trials of PARP Inhibitor Combination Therapy for Prostate Cancer

【免責事項】
https://www.marketreport.jp/reports-disclaimer
★医療情報レポート[PARP阻害剤がん治療の世界市場]についてメールでお問い合わせはこちら

※関連の医療情報レポート

  1. 癌ヤーヌスキナーゼ阻害剤の世界市場機会・治験インサイト
    KUIK80308 / Kuick Research / 2017年10月 / ...“Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023” report gives comprehensive insight on clinical and non-clinical parameters related to development and commercialization of cancer janus kinase inhibitor market. As per report findings, janus kinase inhibitors have emerged as one of the new potential candidate and growth frontier for the various stake holders involved in the research and development of cancer drugs and therapies. At present there is only one janus kinase inhibitors based drug commercially available in the market and 27 drugs are in the various clinical development phases. Most of the drugs are in Preclinical...
  2. 癌チューブリン阻害剤の世界市場・治験インサイト
    KUIK80305 / Kuick Research / 2018年2月 / ...“Global Cancer Tubulin Inhibitors Market & Clinical Trial Insight 2024” report gives comprehensive insight on the clinical and non-clinical parameters related to the emergence and development of role of tubulin inhibitors in the cancer therapy. Report highlights the clinical development of more than 70 cancer tubulin inhibitors in pipeline and shares in-depth dosage/price analysis of 10 cancer tubulin inhibitors commercially available in the market. “Global Cancer Tubulin Inhibitors Market & Clinical Trial Insight 2024” Report highlights: • Clinical Insight on 70 Tubulin Inhibitors in pipeline • Dosage & Price Analysis of 10 Commercialized Drugs • Patent Approval, Expiry Year &...
  3. CD抗原癌治療の世界市場動向・治験インサイト
    KUIK80307 / Kuick Research / 2017年10月 / ...“CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023” report gives comprehensive insight into multiple clinical and non-clinical issues related to emergence and development of global CD Antigen cancer therapy market. CD Antigens have emerged as new growth frontier for the organizations involved in the research, development, licensing and commercialization of targeted cancer therapies. CD antigens have been present in disguise since the efforts began to develop therapeutic monoclonal antibodies in 1970s. CD antigens are the basis on which monoclonal antibodies were discovered. Although the potential of antibodies was well understood but it required a series of discoveries...
  4. 癌CDK阻害剤の世界市場・パイプライン動向
    KUIK80306 / Kuick Research / 2017年11月 / ...“Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook 2022” report gives comprehensive insight on clinical and non-clinical parameters related to emergence and growth of CDK inhibitors in cancer therapy. As per report findings, CDK inhibitors have emerged as new growth frontier for the organizations involved in the research, development, licensing and commercialization of targeted cancer therapies. There are 2 CDK inhibitors commercially available in the market for the treatment of cancer and more than 45 CDK inhibitors are in various phases of clinical pipeline. “Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook 2022” report highlights: • Selectivity &...
  5. 癌mTOR阻害剤の世界市場・パイプライン動向
    KUIK80304 / Kuick Research / 2018年2月 / ...“Global Cancer mTOR Inhibitors Market & Clinical Pipeline Outlook 2022” gives comprehensive insight on the clinical and non-clinical parameters related to the emergence and development of role of mTOR inhibitors in the cancer therapy. Report highlights the clinical development of more than 25 cancer tubulin inhibitors drugs in pipeline and shares in-depth dosage/price analysis of more than 10 cancer mTOR inhibitors drugs commercially available and approved in the market. “Global Cancer mTOR Inhibitors Market & Clinical Pipeline Outlook 2022” Report highlights: • Clinical Insight: 27 mTOR Inhibitors in Pipeline • Commercially Avaliable: 2 mTOR Inhibitors • Working Mechanism of mTOR...
  6. がん抑制遺伝子治療の世界市場及びパイプラインインサイト
    KUICK504091 / KuicK Research / 2015年4月 / 当調査レポートでは、がん抑制遺伝子治療の世界市場について調査・分析し、がん抑制遺伝子治療の世界市場概要、市場の動態、市場展望、がん抑制遺伝子のパイプライン動向、原癌遺伝子タンパク質の種類別・企業別・フェーズ別パイプライン動向、主要企業分析等の情報をお届けいたします。...Oncogenomics is an emerging field that involves screening of genes that may be involved in cancer development. Human genome consists of 23 chromosomal pairs, approximately 20,000- 25,000 genes and 3,234.83 Mb genome size. Oncogene addiction is a phenomenon in which cancer could be checked by deactivating single oncogene. Proto-onco genes are main target of investigators because they may convert into oncogenes at any stage of life. Sequence level similarity and identification of genetic factors are expected to shed more light on their working. It will allow the investigators to develop drugs capable of preventing oncogene activation and activity in the...
  7. 世界のがん治療用キナーゼ阻害剤市場及び製品パイプライン分析
    KUICK4102203 / KuicK Research / 2014年10月 / ...The recent years have witnessed the emergence of kinase inhibitors, which have the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past two decades, the researchers have increased their learning about the functioning of these inhibitors, which has led to the achievement of significant milestones of development during this period. The use of inhibitors for treating cancer is gradually increasing. The rising market availability of these agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body’s acceptance of inhibitors so as...
  8. がん分子標的治療の世界市場及びインサイト
    KUICK504095 / KuicK Research / 2015年4月 / 当調査レポートでは、がん分子標的治療の世界市場について調査・分析し、がん分子標的治療のニーズ、がん分子標的治療の仕組み、がん分子標的治療の世界市場概要、市場の動態、市場展望、がん分子標的モノクローナル抗体のパイプライン動向、がんワクチンのパイプライン動向、原癌遺伝子タンパク質のパイプライン動向、チロシンキナーゼのパイプライン動向、上市品分析、主要企業分析等の情報をお届けいたします。...Cancer targeted therapeutics global market could be broadly divided into small and large molecules segments. Small molecules generate significant shares due to their sheer numbers as compared to large molecules cancer targeted therapeutics. Moreover, they have mature market and they could be considered as pioneer due to which they have more market penetration across the globe. Their prices have gone down because significant progress has been achieved in their drug design development, manufacturing and marketing. However, they have limited targeting efficacy and limited products could be used for multiple cancer indications. This scenario gave way to market introduction of large...
  9. ナノ粒子ドラッグデリバリーの世界市場
    DATA809010 / KuicK Research / 2018年4月 / ...“Global Nanoparticle Drug Delivery Market, Dosage, Price & Clinical Pipeline Outlook 2024” Report Highlights: • Nanoparticle Drug Market: US$ 200 Billion Opportunity By 2024 • Global Pipeline For Nanoparticle Drug: 231 Drugs • Drugs In & Above Phase II Trials: 33 Drugs • Marketed Nanoparticle Drugs: 13 Drugs • Dosage, Price & Patent Analysis Of Key Drugs • Upcoming Nanoparticle Drug Delivery Techniques • Global Nanoparticle Drug Clinical Pipeline by Company, Indication & Phase Drug delivery plays a significant role in determining the therapeutic outcome of a treatment. The limitations of conventional drug delivery system such as low bioavailability of...
  10. 樹状細胞がんワクチンの世界市場展望
    KUIK60306 / KuicK Research / 2016年3月 / ...Dendritic cell first discovered in the early 19th century by Paul Langerhans and their further study and the role it plays in immune system conducted by M. Steinman in 1973, has only received the must deserved attention as a vaccine molecule, in general and as a cancer therapeutics, in particular in the recent past years. There was a widespread skepticism regarding its potential as a vaccine in the scientific community which only eased out with the further ongoing clinical trials. However, gone are the gloomy days for the dendritic cells, the sentinels of the immune system, as its market share...

◆H&Iグローバルリサーチ株式会社のお客様（例）◆